Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome entry site

Laxton, C., Brady, K., Moschos, S.A., Turnpenny, P., Rawal, J., Pryde, D.C., Sidders, B., Corbau, R., Pickford, C. and Murray, E.J. 2011. Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome entry site. Antimicrobial Agents and Chemotherapy. 55 (7), pp. 3105-3114. https://doi.org/10.1128/AAC.00222-11

TitleSelection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome entry site
AuthorsLaxton, C., Brady, K., Moschos, S.A., Turnpenny, P., Rawal, J., Pryde, D.C., Sidders, B., Corbau, R., Pickford, C. and Murray, E.J.
Abstract

We have screened 47 locked nucleic acid (LNA) antisense oligonucleotides (ASOs) targeting conserved (>95% homology) sequences in the hepatitis C virus (HCV) genome using the subgenomic HCV replicon assay and generated both antiviral (50% effective concentration [EC50]) and cytotoxic (50% cytotoxic concentration [CC50]) dose-response curves to allow measurement of the selectivity index (SI). This comprehensive approach has identified an LNA ASO with potent antiviral activity (EC50 = 4 nM) and low cytotoxicity (CC50 >880 nM) targeting the 25- to 40-nucleotide region (nt) of the HCV internal ribosome entry site (IRES) containing the distal and proximal miR-122 binding sites. LNA ASOs targeting previously known accessible regions of the IRES, namely, loop III and the initiation codon in loop IV, had poor SI values. We optimized the LNA ASO sequence by performing a 1-nucleotide walk through the 25- to 40-nt region and show that the boundaries for antiviral efficacy are extremely precise. Furthermore, we have optimized the format for the LNA ASO using different gapmer and mixomer patterns and show that RNase H is required for antiviral activity. We demonstrate that RNase H-refractory ASOs targeting the 25- to 40-nt region have no antiviral effect, revealing important regulatory features of the 25- to 40-nt region and suggesting that RNase H-refractory LNA ASOs can act as potential surrogates for proviral functions of miR-122. We confirm the antisense mechanism of action using mismatched LNA ASOs. Finally, we have performed pharmacokinetic experiments to demonstrate that the LNA ASOs have a very long half-life (>5 days) and attain hepatic maximum concentrations >100 times the concentration required for in vitro antiviral activity.

JournalAntimicrobial Agents and Chemotherapy
Journal citation55 (7), pp. 3105-3114
ISSN0066-4804
YearJul 2011
PublisherAmerican Society for Microbiology
Digital Object Identifier (DOI)https://doi.org/10.1128/AAC.00222-11
Publication dates
PublishedJul 2011

Related outputs

Bacterial Adaptation to Venom in Snakes and Arachnida
Esmaeilishirazifard, Elham, Usher, Louise, Trim, Carol, Denise, Hubert, Sangal, V., Tyson, G., Barlow, Axel, Redway, Keith F, Taylor, John D, Kremyda-Vlachou, Myrto, Davies, Sam, Loftus, Teresa D, Lock, Mikaella M G, Wright, Kstir, Dalby, Andrew, Snyder, L., Wuster, Wolfgang, Trim, Steve and Moschos, S. 2022. Bacterial Adaptation to Venom in Snakes and Arachnida. Microbiology Spectrum. 10 (3) e02408-21. https://doi.org/10.1128/spectrum.02408-21

Extracellular vesicles and their nucleic acids for biomarker discovery
Momen Heravi, F., Getting, S.J. and Moschos, S.A. 2018. Extracellular vesicles and their nucleic acids for biomarker discovery. Pharmacology and Therapeutics. 192, pp. 170-187. https://doi.org/10.1016/j.pharmthera.2018.08.002

A novel antifungal property for the Bacillus licheniformis ComX pheromone and its possible role in inter-kingdom cross-talk
Esmaeilishirazifard, E., Dariush, A., Moschos, S.A. and Keshavarz, T. 2018. A novel antifungal property for the Bacillus licheniformis ComX pheromone and its possible role in inter-kingdom cross-talk. Applied Microbiology and Biotechnology. 102 (12), pp. 5197-5208. https://doi.org/10.1007/s00253-018-9004-7

Clinical potential of oligonucleotide-based therapeutics in the respiratory system
Moschos, S.A., Usher, L. and Lindsay, M.A. 2017. Clinical potential of oligonucleotide-based therapeutics in the respiratory system. Pharmacology and Therapeutics. 169, pp. 83-103. https://doi.org/10.1016/j.pharmthera.2016.10.009

Low Complexity All-Pass Based Polyphase Decimation Filters for ECG Monitoring
Eminaga, Y., Coskun, A., Moschos, S.A. and Kale, I. 2015. Low Complexity All-Pass Based Polyphase Decimation Filters for ECG Monitoring. PRIME 2015, 11th Conference on PhD Research in Microelectronics and Electronics . Glasgow, Scotland 30 Jun 2015 IEEE . https://doi.org/10.1109/PRIME.2015.7251400

Introducing EbolaCheck: potential for point-of-need infectious disease diagnosis
Moschos, S.A. 2015. Introducing EbolaCheck: potential for point-of-need infectious disease diagnosis. Expert Review of Molecular Diagnostics. 15 (10), pp. 1237-1240. https://doi.org/10.1586/14737159.2015.1084228

Investigation on quorum sensing molecule of Bacillus licheniformis and its antifungal property
Esmaeilishirazifard, E., Moschos, S.A. and Keshavarz, T. 2015. Investigation on quorum sensing molecule of Bacillus licheniformis and its antifungal property.

Bio‐control application of Bacillus quorum sensing on aflatoxigenic fungi through their inter‐kingdom cross‐talk
Esmaeilishirazifard, E., Moschos, S.A. and Keshavarz, T. 2015. Bio‐control application of Bacillus quorum sensing on aflatoxigenic fungi through their inter‐kingdom cross‐talk. 6th Congress of European Microbiologists (FEMS 2015). Maastricht, The Netherlands

Inter-kingdom cross-talk and its bio-control applications
Esmaeilishirazifard, E., Moschos, S.A. and Keshavarz, T. 2014. Inter-kingdom cross-talk and its bio-control applications. International Union of Microbiological Societies Congress. Montreal, Canada 31 Jul 2014

Bio-control applications of Bacillus quorum sensing on aflatoxigenic fungi
Esmaeilishirazifard, E., Moschos, S.A. and Keshavarz, T. 2014. Bio-control applications of Bacillus quorum sensing on aflatoxigenic fungi.

Deep sequencing insights in therapeutic shRNA processing and siRNA target cleavage precision
Denise, H., Moschos, S.A., Sidders, B., Burden, F., Perkins, H., Carter, N., Stroud, T., Kennedy, M., Fancy, S.A., Lapthorn, C., Lavender, H., Kinloch, R., Suhy, D.A. and Corbau, R. 2014. Deep sequencing insights in therapeutic shRNA processing and siRNA target cleavage precision. Molecular Therapy Nucleic Acids. 3, p. e145. https://doi.org/10.1038/mtna.2013.73

Interaction between Bacillus species and filamentous fungi for the control of fungal toxin production
Esmaeilishirazifard, E., Moschos, S.A. and Keshavarz, T. 2013. Interaction between Bacillus species and filamentous fungi for the control of fungal toxin production.

MicroRNA biotherapeutics: key challenges from a drug development perspective
Moschos, S.A. 2013. MicroRNA biotherapeutics: key challenges from a drug development perspective. in: Jones, L. and McKnight, A. (ed.) Biotherapeutics: recent developments using chemical and molecular biology London The Royal Society of Chemistry.

Genomic biomarkers for patient selection and stratification: the cancer paradigm
Moschos, S.A. 2012. Genomic biomarkers for patient selection and stratification: the cancer paradigm. Bioanalysis. 4 (20), pp. 2499-2511. https://doi.org/10.4155/bio.12.241

In vivo pharmacology: reaping the benefits of analysis at the cell type level
Moschos, S.A. 2012. In vivo pharmacology: reaping the benefits of analysis at the cell type level. Pharmacology Matters Newsletter. 5 (1), pp. 15-16.

Transcriptome analysis shows activation of circulating CD8+ T cells in patients with severe asthma
Tsitsiou, E., Williams, A.E., Moschos, S.A., Patel, K., Rossios, C., Jiang, X., Adams, O.D., Macedo, P., Booton, R., Gibeon, D., Chung, K.F. and Lindsay, M.A. 2012. Transcriptome analysis shows activation of circulating CD8+ T cells in patients with severe asthma. Journal of Allergy and Clinical Immunology. 129 (1), pp. 95-103. https://doi.org/10.1016/j.jaci.2011.08.011

Relevance of systems pharmacology in drug discovery
Cucurull-Sanchez, L., Spink, K.G. and Moschos, S.A. 2012. Relevance of systems pharmacology in drug discovery. Drug Discovery Today. 17 (13-14), pp. 665-670. https://doi.org/10.1016/j.drudis.2012.01.015

Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model
Suhy, D.A., Kao, S.C., Mao, T., Whiteley, L., Denise, H., Souberbielle, B., Burdick, A.D., Hayes, K., Wright, J.F., Lavender, H., Roelvink, P., Kolykhalov, A., Brady, K., Moschos, S.A., Hauck, B., Zelenaia, O., Zhou, S., Scribner, C., High, K.A., Renison, S.H. and Corbau, R. 2012. Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model. Molecular Therapy. 20 (9), pp. 1737-1749. https://doi.org/10.1038/mt.2012.119

The 3 prime paradigm of the miR-200 family and other microRNAs
Brock, G.J., Moschos, S.A., Spivack, S.D. and Hurteau, G.J. 2011. The 3 prime paradigm of the miR-200 family and other microRNAs. Epigenetics. 6 (3), pp. 268-272. https://doi.org/10.4161/epi.6.3.14635

Measuring the action of CPP–siRNA conjugates in the lung
Moschos, S.A., Spink, K.G. and Lindsay, M.A. 2011. Measuring the action of CPP–siRNA conjugates in the lung. Methods in Molecular Biology. 683 (5), pp. 417-429. https://doi.org/10.1007/978-1-60761-919-2_30

Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense
Moschos, S.A., Frick, M., Taylor, B., Turnpenny, P., Graves, H., Spink, K.G., Brady, K., Lambiel, D., Collins, D., Rockel, T., Weber, M., Lazari, O., Perez-Tosar, L., Fancy, S.A., Lapthorn, C., Green, M.X., Evans, S., Selby, M., Jones, G., Jones, L., Kearney, S., Mechiche, H., Gikunju, D., Subramanian, R., Uhlmann, E., Jurk, M., Vollmer, J., Ciaramella, G. and Yeadon, M. 2011. Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense. Molecular Therapy. 19 (12), pp. 2163-2168. https://doi.org/10.1038/mt.2011.206

Is it in yet? Optimisation and screening of an RNAi delivery screen
Lazari, O., Moschos, S.A., Kearney, S., Green, M.P. and Spink, K.G. 2011. Is it in yet? Optimisation and screening of an RNAi delivery screen. ELRIG 2011, Spring Meeting.

The role of miRNA in diagnostics
Moschos, S.A. 2010. The role of miRNA in diagnostics. International Drug Discovery. Online only.

Flow cytometric identification of cell types in digested mouse lung
Graves, H., Taylor, B., Mechiche, H. and Moschos, S.A. 2010. Flow cytometric identification of cell types in digested mouse lung. 9th Annual Symposium on Biopharmaceuticals - San Diego Bio-Pharma Conference. Hilton San Diego/Del Mar, Del Mar 05 Jun 2010

Role of miRNA-146a in the regulation of the innate immune response and cancer
Williams, A.E., Perry, M.M., Moschos, S.A., Larner-Svensson, H.M. and Lindsay, M.A. 2008. Role of miRNA-146a in the regulation of the innate immune response and cancer. Biochemical Society. Transactions. 36 (6), pp. 1211-1215. https://doi.org/10.1042/BST0361211

Rapid changes in microRNA-146a expression negatively regulate the IL-1β-induced inflammatory response in human lung alveolar epithelial cells
Perry, M.M., Moschos, S.A., Williams, A.E., Shepherd, N.J., Larner-Svensson, H.M. and Lindsay, M.A. 2008. Rapid changes in microRNA-146a expression negatively regulate the IL-1β-induced inflammatory response in human lung alveolar epithelial cells. Journal of Immunology. 180 (8), pp. 5689-5698.

Targeting the lung using siRNA and antisense based oligonucleotides
Moschos, S.A., Spink, K.G., Williams, A.E. and Lindsay, M.A. 2008. Targeting the lung using siRNA and antisense based oligonucleotides. Current Pharmaceutical Design. 14 (34), pp. 3620-3627.

Cell-penetrating-peptide-mediated siRNA lung delivery
Moschos, S.A., Williams, A.E. and Lindsay, M.A. 2007. Cell-penetrating-peptide-mediated siRNA lung delivery. Biochemical Society. Transactions. 35 (4), pp. 807-810.

Maternally imprinted microRNAs are differentially expressed during mouse and human lung development
Williams, A.E., Moschos, S.A., Perry, M.M., Barnes, P.J. and Lindsay, M.A. 2007. Maternally imprinted microRNAs are differentially expressed during mouse and human lung development. Developmental Dynamics. 236 (2), pp. 572-580. https://doi.org/10.1002/dvdy.21047

microRNA expression in the aging mouse lung
Williams, A.E., Perry, M.M., Moschos, S.A. and Lindsay, M.A. 2007. microRNA expression in the aging mouse lung. BMC Genomics. 8 (1), p. 172. https://doi.org/10.1186/1471-2164-8-172

MicroRNAs are differentially expressed in the developing lung but not in the aged lung
Williams, A.E., Moschos, S.A., Perry, M.M. and Lindsay, M.A. 2007. MicroRNAs are differentially expressed in the developing lung but not in the aged lung. Proceedings of the American Thoracic Society 2007 International Conference. San Francisco 18 - 23 May 2007 pp. A558

MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity
Turner, J.J., Jones, S.W., Moschos, S.A., Lindsay, M.A. and Gait, M.J. 2007. MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity. Molecular BioSystems. 3 (1), pp. 43-50. https://doi.org/10.1039/B611612D

ncreased expression of microRNA-146a/b negatively regulates IL-1b induced cytokine release from airway epithelial cells
Perry, M.M., Moschos, S.A., Williams, A.E. and Lindsay, M.A. 2007. ncreased expression of microRNA-146a/b negatively regulates IL-1b induced cytokine release from airway epithelial cells. Proceedings of the American Thoracic Society 2007 International Conference. San Francisco 18 - 23 May 2007 pp. A239

Expression profiling in vivo demonstrates rapid changes in lung microRNA levels following lipopolysaccharide-induced inflammation but not in the anti-inflammatory action of glucocorticoids
Moschos, S.A., Williams, A.E., Perry, M.M., Birrell, M.A., Belvisi, M.G. and Lindsay, M.A. 2007. Expression profiling in vivo demonstrates rapid changes in lung microRNA levels following lipopolysaccharide-induced inflammation but not in the anti-inflammatory action of glucocorticoids. BMC Genomics. 8 (1), p. 240. https://doi.org/10.1186/1471-2164-8-240

Expression profiling implicates microRNA expression in the resolution of the inflammatory response in vivo
Moschos, S.A., Perry, M.M., Williams, A.E. and Lindsay, M.A. 2007. Expression profiling implicates microRNA expression in the resolution of the inflammatory response in vivo. Proceedings of the American Thoracic Society 2007 International Conference. San Francisco 18 - 23 May 2007 pp. A239

Lung delivery studies using siRNA conjugated to TAT(48−60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity
Moschos, S.A., Jones, S.W., Perry, M.M., Williams, A.E., Erjefalt, J.S., Turner, J.J., Barnes, P.J., Sproat, B.S., Gait, M.J. and Lindsay, M.A. 2007. Lung delivery studies using siRNA conjugated to TAT(48−60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjugate Chemistry. 18 (5), pp. 1450-1459. https://doi.org/10.1021/bc070077d

In vitro and in vivo delivery studies of siRNA-peptide conjugates
Turner, J.J., Fabani, M.M., Jones, S.W., Moschos, S.A., Perry, M.M., Lindsay, M.A. and Gait, M.J. 2006. In vitro and in vivo delivery studies of siRNA-peptide conjugates. Journal of RNAi and Gene Silencing. 2 (2), pp. 171-172.

Modulating the adjuvanticity of alum by co-administration of muramyl di-peptide (MDP) or Quil-A
Moschos, S.A. and Bramwell, V.W. 2006. Modulating the adjuvanticity of alum by co-administration of muramyl di-peptide (MDP) or Quil-A. Vaccine. 24 (8), pp. 1081-1086. https://doi.org/10.1016/j.vaccine.2005.09.007

Comparative immunomodulatory properties of a chitosan-MDP adjuvant combination following intranasal or intramuscular immunisation
Moschos, S.A., Bramwell, V.W., Somavarapu, S. and Alpar, H.O. 2005. Comparative immunomodulatory properties of a chitosan-MDP adjuvant combination following intranasal or intramuscular immunisation. Vaccine. 23 (16), pp. 1923-1930. https://doi.org/10.1016/j.vaccine.2004.10.016

Adjuvant synergy: the effects of nasal coadministration of adjuvants
Moschos, S.A., Bramwell, V.W., Somavarapu, S. and Alpar, H.O. 2004. Adjuvant synergy: the effects of nasal coadministration of adjuvants. Immunology and Cell Biology. 82 (6), pp. 628-637. https://doi.org/10.1111/j.0818-9641.2004.01280.x

New strategies in vaccine research: targeting quorum sensing pathways for prophylaxis against antibiotic-resistant S. aureus infections
Moschos, S.A., Pandit, S., Somavarapu, S., Balaban, N. and Alpar, H.O. 2004. New strategies in vaccine research: targeting quorum sensing pathways for prophylaxis against antibiotic-resistant S. aureus infections. Proceedings of the 31st International Symposium for the Controlled Release of Bioactive Materials 2004. Honolulu, USA 12 - 16 Jun 2004 pp. 526

Double identity
Moschos, S.A. 2003. Double identity. New Scientist. 2424.

Considerations in the antigen-stimulated, primed, primary splenocyte culture model as an in vitro vaccine screening tool
Moschos, S.A., Bramwell, V.W. and Alpar, H.O. 2003. Considerations in the antigen-stimulated, primed, primary splenocyte culture model as an in vitro vaccine screening tool. Proceedings of the 30th International Symposium for the Controlled Release of Bioactive Materials. Glasgow 19 - 23 Jul 2003 pp. 899

Immunogenicity of adjuvanted recombinant urease administered intranasally
Moschos, S.A., Somavarapu, S., Singh, J., Bramwell, V.W., Randall, L., Guy, B. and Alpar, H.O. 2001. Immunogenicity of adjuvanted recombinant urease administered intranasally. Proceedings of the 28th International Symposium for the Controlled Release of Bioactive Materials. San Diego, USA 23 - 27 Jun 2001 pp. 7033

Immunogenicity of adjuvanted recombinant urease administered intra-muscularly
Moschos, S.A., Somavarapu, S., Eyles, J.E., McHugh, C., Bramwell, V.W., Randall, L., Guy, B. and Alpar, H.O. 2001. Immunogenicity of adjuvanted recombinant urease administered intra-muscularly. Proceedings of the 28th International Symposium for the Controlled Release of Bioactive Materials. San Diego, USA 23 - 27 Jun 2001 pp. 7033

Evaluation of adjuvanted recombinant urease for effective immunization against Helicobacter pylori
Moschos, S.A., Somavarapu, S., Eyles, J.E., McHugh, C., Bramwell, V.W., Randall, L., Guy, B. and Alpar, H.O. 2001. Evaluation of adjuvanted recombinant urease for effective immunization against Helicobacter pylori. Immunology. 104 (s1), p. 98. https://doi.org/10.1046/j.1365-2567.2001.1040s1070.x

Quil-A and MDP enhances the adjuvanticity of alum for intramuscular delivery of rURE
Moschos, S.A., Somavarapu, S., Bramwell, V.W., Randall, L., Guy, B. and Alpar, H.O. 2001. Quil-A and MDP enhances the adjuvanticity of alum for intramuscular delivery of rURE. Immunology. 104 (s1), p. 98. https://doi.org/10.1046/j.1365-2567.2001.1040s1070.x

Microsphere encapsulated Diphtheria Toxoid induces protein secretion from in-vitro Peyers’ patches and in vivo
Turner, J.J., Somavarapu, S., Moschos, S.A., Randall, L., Simpkin, G. and Alpar, H.O. 2000. Microsphere encapsulated Diphtheria Toxoid induces protein secretion from in-vitro Peyers’ patches and in vivo. Proceedings of the 3rd World Meeting APV/APGI 2000. Berlin, Germany 3 - 6 Apr 2000 pp. 389-390

Novel protein secretion from both ex-vivo Peyers’ patches and in-vivo; induction by microsphere encapsulated diphtheria toxoid
Moschos, S.A., Somavarapu, S., Singh, J., Bramwell, V.W., Randall, L., Guy, B. and Alpar, H.O. 2000. Novel protein secretion from both ex-vivo Peyers’ patches and in-vivo; induction by microsphere encapsulated diphtheria toxoid. Proceedings of the 27th International Symposium for the Controlled Release of Bioactive Materials. Paris, France 09 - 13 Jul 2001 pp. 562-563

Permalink - https://westminsterresearch.westminster.ac.uk/item/8zv37/selection-optimization-and-pharmacokinetic-properties-of-a-novel-potent-antiviral-locked-nucleic-acid-based-antisense-oligomer-targeting-hepatitis-c-virus-internal-ribosome-entry-site


Share this

Usage statistics

137 total views
0 total downloads
These values cover views and downloads from WestminsterResearch and are for the period from September 2nd 2018, when this repository was created.